TandemAI announced it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M.

With a team of more than 300 professionals, TandemAI’s AI-powered, fully integrated drug discovery engine has delivered over ten high-value, highly differentiated candidates that are now in—or soon to enter—clinical development. The company has also partnered with four of the world’s top ten multinational pharmaceutical companies, building a network of more than 150 global partners and clients.

Marketing Technology News: MarTech Interview with Julian Highley, EVP, Global Data Science & Product @ MarketCast

“TandemAI has successfully executed on its approach to build and commercialize a powerful drug discovery platform by integrating AI and physics-based computational technologies with wet lab techniques,” said Peter Zhao, Managing Director at V-Capital. “With this funding, the company and its outstanding team are well positioned to grow its existing small molecule business and, with the recent merger with Perpetual Medicines, capitalize on the significant emerging opportunities in peptide and antibody-peptide conjugate discovery.”

KHK Fund stated, “AI and advanced physics-based methods are now essential for drug discovery. TandemAI’s platform has notably enhanced R&D efficiency and success rates in small molecule and peptide drug discovery, driving rapid growth even during the pharmaceutical market downturn. We are pleased to support the company’s continued growth.”

Marketing Technology News: Martech & the ‘Digital Unconscious’: Unearthing Hidden Consumer Motivations

“The financing is a strong vote of confidence in our progress to date and in our strategy,” said Jeff He, co-founder and CEO of TandemAI. “This funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base.” Mr. He noted that the strategic merger with Perpetual Medicines also brought on board seasoned drug developers Kerry Blanchard, MD, PhD and Ved Srivastava, PhD, further enhancing TandemAI’s end-to-end drug discovery and development expertise.